Skip to main content
. 2015 Aug 18;6(30):30232–30238. doi: 10.18632/oncotarget.4920

Figure 4. Model for classification of gliomas based on molecular markers.

Figure 4

IDH1/2 mutant tumors with low and moderate Ki-67 expression was termed as Group 1, IDH1/2 mutant tumors with high Ki-67 expression as Group 2, IDH1/2 wt tumors with low Ki-67 expression as Group 3, IDH wt tumors with moderate Ki-67 expression as Group 4, and IDH wt tumors with high Ki-67 expression was defined as Group 5.